Intra-Cellular Therapies (NASDAQ:ITCI) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Intra-Cellular Therapies (NASDAQ:ITCI) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08), Zacks reports. The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%.

Intra-Cellular Therapies Stock Performance

Shares of ITCI opened at $128.60 on Friday. The stock has a market capitalization of $13.67 billion, a PE ratio of -147.81 and a beta of 0.72. Intra-Cellular Therapies has a 1 year low of $62.78 and a 1 year high of $128.77. The company’s 50-day simple moving average is $110.27 and its 200-day simple moving average is $89.64.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

ITCI has been the topic of several recent research reports. Royal Bank of Canada reissued a “sector perform” rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their target price for the company from $119.00 to $132.00 in a research report on Friday, January 31st. JPMorgan Chase & Co. upped their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Nine investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and an average target price of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.